ZURICH, July 4 (Reuters) - Italy’s Cosmo Pharmaceuticals said on Wednesday a mid- to late-stage trial of its Rifamycin drug in infectious diarrhoea had met its primary objective, boosting the biotech company’s shares.
ZURICH, July 4 (Reuters) - Italy’s Cosmo Pharmaceuticals said on Wednesday a mid- to late-stage trial of its Rifamycin drug in infectious diarrhoea had met its primary objective, boosting the biotech company’s shares.
